IN2012DN02345A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02345A
IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
Authority
IN
India
Prior art keywords
nucleic acid
stranded
methods
tlrs
relates
Prior art date
Application number
Inventor
Bruce A Sullenger
Jaewoo Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IN2012DN02345A publication Critical patent/IN2012DN02345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid ("nucleic acid binding agent"), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.
IN2345DEN2012 2009-09-16 2010-09-16 IN2012DN02345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
PCT/US2010/002516 WO2011034583A2 (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Publications (1)

Publication Number Publication Date
IN2012DN02345A true IN2012DN02345A (en) 2015-08-21

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2345DEN2012 IN2012DN02345A (en) 2009-09-16 2010-09-16

Country Status (6)

Country Link
US (3) US9468650B2 (en)
EP (1) EP2477641B1 (en)
CN (1) CN102639142A (en)
CA (1) CA2774460C (en)
IN (1) IN2012DN02345A (en)
WO (1) WO2011034583A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702917A (en) 2007-03-30 2010-05-05 杜克大学 A method of modulating the activity of a nucleic acid molecule
CN102639142A (en) 2009-09-16 2012-08-15 杜克大学 Inhibition of endosomal toll-like receptor activation
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
WO2014169043A1 (en) * 2013-04-09 2014-10-16 Duke University Anti-inflammatory agents and methods of using the same
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
US10889816B2 (en) 2016-09-16 2021-01-12 Duke University Von Willebrand Factor (VWF)—targeting agents and methods of using the same
US11634772B2 (en) 2017-03-23 2023-04-25 Duke University Antidote-mediated reversal of extracellular aptamer staining
US20200171167A1 (en) * 2017-05-30 2020-06-04 The Trustees Of Columbia University In The City Of New York Cationic nucleic acid scavenger and uses thereof
WO2021016924A1 (en) * 2019-07-31 2021-02-04 中山大学 Cationic polymer and particles usable to treat psoriasis
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
WO2002019822A1 (en) 2000-09-08 2002-03-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1347776A2 (en) * 2001-01-05 2003-10-01 Intercell Biomedizinische Forschungs- und Entwicklungs AG Anti-inflammatory use of polycationic compounds
RU2003129062A (en) 2001-03-08 2005-04-10 Мерк Патент ГмбХ (DE) MODIFIED PROTAMIN WITH REDUCED IMMUNOGENITY
JP4773684B2 (en) 2001-05-25 2011-09-14 デューク ユニバーシティ Drug modulator
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) * 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
JP2005527639A (en) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Methods and compositions for therapeutic use of RNA interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
CN1717209A (en) 2002-10-09 2006-01-04 植入疗法公司 Cyclodextrin-based materials, compositions and uses related thereto
EP1649019A2 (en) 2003-07-15 2006-04-26 California Institute Of Technology Improved inhibitor nucleic acids
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4718541B2 (en) 2004-04-22 2011-07-06 リガド・バイオサイエンシーズ・インコーポレーテツド Improved coagulation factor regulator
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
GB0422877D0 (en) * 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
DK1866414T3 (en) 2005-03-31 2012-04-23 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof.
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
RU2568579C2 (en) 2006-05-26 2015-11-20 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Introduction of anti-coagulating system reg1
EP3669894A3 (en) * 2006-06-30 2020-08-26 Syntab Therapeutics GmbH Novel multifunctional compounds for pharmaceutical purposes
US20110118187A1 (en) 2006-10-19 2011-05-19 Duke University Reversible platelet inhibition
US20100028402A1 (en) 2006-10-25 2010-02-04 Marina Dobrovolskaia Nanoparticle-based anticoagulant
WO2008100598A2 (en) * 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
CN101702917A (en) 2007-03-30 2010-05-05 杜克大学 A method of modulating the activity of a nucleic acid molecule
WO2009041870A1 (en) 2007-09-27 2009-04-02 Sca Hygiene Products Ab Claylinked polymer gels
US20100285081A1 (en) 2007-11-12 2010-11-11 Massachusetts Institute Of Technology Bactericidal Nanofibers, and Methods of Use Thereof
WO2010020008A1 (en) 2008-08-22 2010-02-25 Polymers Crc Limited Polymer coatings
US8992991B2 (en) 2009-05-15 2015-03-31 The Johns Hopkins University Multicomponent degradable cationic polymers
CN102639142A (en) 2009-09-16 2012-08-15 杜克大学 Inhibition of endosomal toll-like receptor activation
WO2012088059A2 (en) 2010-12-20 2012-06-28 Virginia Commonwealth University A facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance

Also Published As

Publication number Publication date
CN102639142A (en) 2012-08-15
US20120183564A1 (en) 2012-07-19
US20230248805A1 (en) 2023-08-10
CA2774460C (en) 2016-08-09
US20170095503A1 (en) 2017-04-06
EP2477641A4 (en) 2013-08-07
CA2774460A1 (en) 2011-03-24
US11617779B2 (en) 2023-04-04
US9468650B2 (en) 2016-10-18
WO2011034583A3 (en) 2011-10-06
EP2477641A2 (en) 2012-07-25
WO2011034583A2 (en) 2011-03-24
EP2477641B1 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
IN2012DN02345A (en)
Haas et al. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation
WO2007136736A3 (en) Methods for nucleic acid sorting and synthesis
MX2010002113A (en) Methods for detecting oligonucleotides.
WO2006029258A3 (en) Aptamer medicinal chemistry
HK1116836A1 (en) Multicomponent nucleic acid enzymes and methods for their use
MX2015005328A (en) Compositions and methods for selective delivery of oligonucleotide molecules to cell types.
WO2010026488A3 (en) Methods and kits for nucleic acid sequencing
BR112014007852A2 (en) modified nucleosides, nucleotides and nucleic acids and their uses
IN2014DN03463A (en)
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
WO2008061537A3 (en) Oligonucleotides for modulating target rna activity
SG170802A1 (en) Systems and devices for sequence by synthesis analysis
EP2569453A4 (en) Nucleic acid isolation methods
WO2005097993A3 (en) Immunostimulatory viral rna oligonucleotides
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
EP3358014A3 (en) Method for stabilizing functional nucleic acids
EP2647711A3 (en) Alternative export pathways for vector expressed RNA interference
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
ATE534737T1 (en) TARGETED DELIVERY OF SIRNA
MX2007004686A (en) Multidomain rna molecules comprising at least one aptamer for delivering double stranded rna to pest organisms.
MXPA02000819A (en) Tenascin c nucleic acid ligands.
WO2009002937A3 (en) Methods for isolating long fragment rna from fixed samples
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds